ORMP
Oramed Pharmaceuticals, Inc

4,682
Mkt Cap
$135.73M
Volume
68,013.00
52W High
$3.71
52W Low
$1.82
PE Ratio
3.40
ORMP Fundamentals
Price
$3.45
Prev Close
$3.41
Open
$3.45
50D MA
$3.09
Beta
0.72
Avg. Volume
324,853.45
EPS (Annual)
-$0.4668
P/B
0.69
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving Average - Time to Sell?
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average - Should You Sell...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Increase in Short Interest
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 424,089...
MarketBeat·18d ago
News Placeholder
Oramed and Lifeward Announce Strategic Transaction
Oramed and Lifeward Announce Strategic Transaction Oramed and Lifeward Announce Strategic Transaction PR Newswire NEW YORK, Jan. 13, 2026 Transaction Will TransferOramed's Oral Drug Delivery Platform...
PR Newswire·22d ago
News Placeholder
Oramed Reports Fiscal Third Quarter 2025 Financial Results
Oramed Reports Fiscal Third Quarter 2025 Financial Results Oramed Reports Fiscal Third Quarter 2025 Financial Results PR Newswire NEW YORK, Nov. 17, 2025 Strong Nine-Month Performance Driven by...
PR Newswire·3mo ago
News Placeholder
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS PR Newswire NEW...
PR Newswire·3mo ago
News Placeholder
Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives Oramed Releases Letter to...
PR Newswire·3mo ago
<
...
1
>

Latest ORMP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.